​

Sotera Health (SHC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SHC Stock Forecast

Sotera Health stock forecast is as follows: an average price target of $16.00 (represents a 16.96% upside from SHC’s last price of $13.68) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

SHC Price Target

The average price target for Sotera Health (SHC) is $16.00 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $15.00. This represents a potential 16.96% upside from SHC's last price of $13.68.

SHC Analyst Ratings

Buy

According to 12 Wall Street analysts, Sotera Health's rating consensus is 'Buy'. The analyst rating breakdown for SHC stock is 0 'Strong Buy' (0.00%), 6 'Buy' (50.00%), 5 'Hold' (41.67%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Sotera Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024David WindleyJefferies$15.00$12.9815.56%9.65%
Nov 06, 2024David WindleyJefferies$18.00$15.2717.88%31.58%
Aug 06, 2024Luke SergottBarclays$17.00$14.2219.55%24.27%
Jun 06, 2024David WindleyJefferies$14.50$11.9821.04%5.99%
May 21, 2024Jason BednarPiper Sandler$13.00$10.9119.16%-4.97%
May 03, 2024Sean DodgeRBC Capital$17.00$10.9155.82%24.27%
Apr 10, 2024Luke SergottBarclays$14.00$11.6220.48%2.34%
Mar 25, 2024David WindleyJefferies$15.50$11.9429.87%13.30%
Jun 26, 2023Matthew MishanLoop Capital Markets$24.00$18.5929.14%75.44%
Jan 10, 2023Mike PolarkWolfe Research$25.00$17.2544.93%82.75%
Jan 10, 2023Luke SergottBarclays$22.00$17.2527.54%60.82%
Nov 23, 2022Goldman Sachs$8.00$8.12-1.42%-41.52%
Nov 15, 2022Barclays$6.00$7.13-15.91%-56.14%

The latest Sotera Health stock forecast, released on Dec 05, 2024 by David Windley from Jefferies, set a price target of $15.00, which represents a 15.56% increase from the stock price at the time of the forecast ($12.98), and a 9.65% increase from SHC last price ($13.68).

Sotera Health Price Target by Period

1M3M12M
# Anlaysts-28
Avg Price Target-$16.50$15.50
Last Closing Price$13.68$13.68$13.68
Upside/Downside-100.00%20.61%13.30%

In the current month, the average price target of Sotera Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sotera Health's last price of $13.68. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024JefferiesBuyBuyHold
Nov 05, 2024CitigroupBuyBuyHold
Aug 06, 2024BarclaysOverweightOverweightHold
Aug 05, 2024KeyBancSector WeightSector WeightHold
Jun 06, 2024JefferiesBuyBuyHold
May 21, 2024RBC CapitalBuyBuyHold
May 21, 2024Piper SandlerNeutralInitialise
May 03, 2024RBC CapitalOutperformOutperformHold
Apr 03, 2024RBC CapitalBuyBuyHold
Apr 03, 2024JefferiesUnderperformUnderperformHold
Apr 03, 2024CitigroupNeutralBuyUpgrade
Mar 25, 2024JefferiesBuyUpgrade
Mar 11, 2024BarclaysUnderperformUnderperformHold
Mar 11, 2024RBC CapitalOutperformOutperformHold
Feb 28, 2024BarclaysOverweightOverweightHold
Jun 26, 2023William BlairOutperformInitialise
Jun 26, 2023KeyBancOverweightUpgrade
Jan 23, 2023J.P. MorganNeutralUpgrade
Jan 10, 2023Wolfe ResearchOutperformUpgrade
Jan 10, 2023BarclaysUnderweightOverweightUpgrade
Nov 23, 2022Goldman SachsNeutralNeutralHold
Nov 15, 2022BarclaysEqual-WeightUnderweightDowngrade
Oct 05, 2022Compass PointNegativeUpgrade
Oct 05, 2022New StreetNeutralUpgrade
Oct 05, 2022CitigroupNeutralDowngrade
Jul 13, 2022BarclaysEqual-WeightEqual-WeightHold

Sotera Health's last stock rating was published by Jefferies on Dec 05, 2024. The company gave SHC a "Buy" rating, the same as its previous rate.

Sotera Health Financial Forecast

Sotera Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue------------$310.24M$263.18M$255.28M$220.59M$251.59M$248.70M$266.64M$236.75M$241.25M$226.16M$251.92M$212.15M$216.84M
Avg Forecast$328.89M$310.35M$302.68M$271.58M$306.72M$295.22M$290.04M$259.56M$290.70M$278.64M$266.45M$244.38M$302.17M$264.55M$258.93M$221.03M$247.46M$248.20M$256.30M$230.17M$236.37M$221.61M$227.24M$207.38M$209.12M
High Forecast$338.91M$319.82M$311.91M$279.86M$316.07M$304.22M$298.88M$266.11M$293.21M$278.82M$266.45M$244.38M$303.65M$264.55M$266.82M$227.77M$253.79M$248.20M$256.30M$230.17M$236.37M$221.61M$227.24M$207.38M$209.12M
Low Forecast$322.77M$304.58M$297.05M$266.53M$301.02M$289.73M$284.64M$253.61M$288.76M$278.46M$266.45M$244.38M$300.70M$264.55M$254.11M$216.92M$241.74M$248.20M$256.30M$230.17M$236.37M$221.61M$227.24M$207.38M$209.12M
# Analysts2222111454224222111122222
Surprise %------------1.03%0.99%0.99%1.00%1.02%1.00%1.04%1.03%1.02%1.02%1.11%1.02%1.04%

Sotera Health's average Quarter revenue forecast for Mar 24 based on 2 analysts is $244.38M, with a low forecast of $244.38M, and a high forecast of $244.38M. SHC's average Quarter revenue forecast represents a -21.23% decrease compared to the company's last Quarter revenue of $310.24M (Dec 23).

Sotera Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts2222111454224222111122222
EBITDA------------$104.02M$76.10M$81.78M$50.85M$78.02M$101.01M$107.95M$92.51M$74.34M$96.88M$118.41M$72.80M$49.15M
Avg Forecast$106.21M$100.23M$97.75M$87.71M$99.05M$95.34M$93.67M$83.82M$93.88M$89.98M$86.05M$78.92M$97.59M$85.43M$83.62M$71.38M$79.92M$96.61M$99.76M$81.53M$92.00M$86.26M$88.45M$63.70M$81.40M
High Forecast$109.45M$103.28M$100.73M$90.38M$102.07M$98.25M$96.52M$85.94M$94.69M$90.04M$86.05M$78.92M$98.06M$85.44M$86.17M$73.56M$81.96M$96.61M$99.76M$97.83M$92.00M$86.26M$88.45M$76.44M$81.40M
Low Forecast$104.24M$98.36M$95.93M$86.07M$97.21M$93.57M$91.92M$81.90M$93.25M$89.93M$86.05M$78.92M$97.11M$85.43M$82.06M$70.05M$78.07M$96.61M$99.76M$65.22M$92.00M$86.26M$88.45M$50.96M$81.40M
Surprise %------------1.07%0.89%0.98%0.71%0.98%1.05%1.08%1.13%0.81%1.12%1.34%1.14%0.60%

2 analysts predict SHC's average Quarter EBITDA for Mar 24 to be $78.92M, with a high of $78.92M and a low of $78.92M. This is -24.13% lower than Sotera Health's previous annual EBITDA (Dec 23) of $104.02M.

Sotera Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts2222111454224222111122222
Net Income------------$38.68M$-13.66M$23.51M$2.84M$-319.72M$25.09M$30.42M$30.64M$36.00M$27.44M$42.60M$10.84M$-43.68M
Avg Forecast$73.07M$65.64M$63.20M$45.93M$65.68M$61.70M$56.84M$40.36M$57.69M$52.20M$47.03M$35.47M$73.60M$56.52M$52.24M$38.85M$62.56M$63.79M$68.87M$27.24M$63.02M$57.97M$59.19M$9.49M$21.37M
High Forecast$75.96M$68.24M$65.70M$47.75M$68.28M$64.15M$59.10M$43.25M$59.98M$52.32M$47.07M$35.50M$79.27M$56.53M$54.31M$40.38M$64.64M$63.79M$68.87M$32.68M$63.02M$57.97M$59.19M$11.38M$21.37M
Low Forecast$71.30M$64.05M$61.67M$44.82M$64.09M$60.21M$55.47M$39.38M$54.94M$52.09M$46.98M$35.44M$70.77M$56.51M$50.98M$37.91M$60.68M$63.79M$68.87M$21.79M$63.02M$57.97M$59.19M$7.59M$21.37M
Surprise %------------0.53%-0.24%0.45%0.07%-5.11%0.39%0.44%1.13%0.57%0.47%0.72%1.14%-2.04%

Sotera Health's average Quarter net income forecast for Mar 24 is $35.47M, with a range of $35.44M to $35.50M. SHC's average Quarter net income forecast represents a -8.29% decrease compared to the company's last Quarter net income of $38.68M (Dec 23).

Sotera Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts2222111454224222111122222
SG&A------------$60.36M$54.11M$60.29M$61.91M$65.95M$57.09M$63.13M$59.54M$51.83M$44.04M$49.83M$52.47M$68.20M
Avg Forecast$71.75M$67.71M$66.03M$59.25M$66.91M$64.40M$63.27M$56.62M$63.42M$60.79M$58.13M$53.31M$65.92M$57.71M$56.49M$48.22M$53.98M$50.37M$52.02M$52.93M$47.97M$44.98M$46.12M$45.91M$42.44M
High Forecast$73.94M$69.77M$68.05M$61.05M$68.95M$66.37M$65.20M$58.05M$63.97M$60.83M$58.13M$53.31M$66.24M$57.71M$58.21M$49.69M$55.37M$50.37M$52.02M$63.51M$47.97M$44.98M$46.12M$55.09M$42.44M
Low Forecast$70.41M$66.45M$64.80M$58.15M$65.67M$63.21M$62.10M$55.33M$63.00M$60.75M$58.13M$53.31M$65.60M$57.71M$55.44M$47.32M$52.74M$50.37M$52.02M$42.34M$47.97M$44.98M$46.12M$36.73M$42.44M
Surprise %------------0.92%0.94%1.07%1.28%1.22%1.13%1.21%1.13%1.08%0.98%1.08%1.14%1.61%

Sotera Health's average Quarter SG&A projection for Mar 24 is $53.31M, based on 2 Wall Street analysts, with a range of $53.31M to $53.31M. The forecast indicates a -11.67% fall compared to SHC last annual SG&A of $60.36M (Dec 23).

Sotera Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts2222111454224222111122222
EPS------------$0.14$-0.05$0.08$0.01$-1.14$0.09$0.11$0.11$0.13$0.10$0.15$0.04$-0.17
Avg Forecast$0.26$0.23$0.22$0.16$0.23$0.22$0.20$0.14$0.20$0.18$0.16$0.12$0.26$0.20$0.18$0.14$0.22$0.22$0.24$0.19$0.22$0.20$0.21$0.16$0.08
High Forecast$0.27$0.24$0.23$0.17$0.24$0.22$0.21$0.15$0.21$0.18$0.16$0.12$0.28$0.20$0.19$0.14$0.23$0.22$0.24$0.19$0.22$0.20$0.21$0.16$0.08
Low Forecast$0.25$0.22$0.22$0.16$0.22$0.21$0.19$0.14$0.19$0.18$0.16$0.12$0.25$0.20$0.18$0.13$0.21$0.22$0.24$0.19$0.22$0.20$0.21$0.16$0.08
Surprise %------------0.54%-0.25%0.44%0.07%-5.20%0.40%0.45%0.57%0.59%0.49%0.72%0.25%-2.26%

According to 2 Wall Street analysts, Sotera Health's projected average Quarter EPS for Mar 24 is $0.12, with a low estimate of $0.12 and a high estimate of $0.12. This represents a -11.27% decrease compared to SHC previous annual EPS of $0.14 (Dec 23).

Sotera Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ACRSAclaris Therapeutics$2.36$6.00154.24%Buy
MYGNMyriad Genetics$12.54$30.20140.83%Hold
ICLRICON Public$198.12$337.0070.10%Buy
NEOGNeogen$11.50$17.5052.17%Buy
RDNTRadNet$67.17$89.0032.50%Buy
IQVIQVIA$198.07$249.6326.03%Buy
XGNExagen$4.07$5.0022.85%Buy
SHCSotera Health$13.68$16.0016.96%Buy
QGENQiagen$43.77$49.0011.95%Buy
MEDPMedpace$343.02$369.677.77%Hold

SHC Forecast FAQ

Is Sotera Health a good buy?

Yes, according to 12 Wall Street analysts, Sotera Health (SHC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 50.00% of SHC's total ratings.

What is SHC's price target?

Sotera Health (SHC) average price target is $16 with a range of $15 to $17, implying a 16.96% from its last price of $13.68. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sotera Health stock go up soon?

According to Wall Street analysts' prediction for SHC stock, the company can go up by 16.96% (from the last price of $13.68 to the average price target of $16), up by 24.27% based on the highest stock price target, and up by 9.65% based on the lowest stock price target.

Can Sotera Health stock reach $20?

SHC's average twelve months analyst stock price target of $16 does not support the claim that Sotera Health can reach $20 in the near future.

What are Sotera Health's analysts' financial forecasts?

Sotera Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.15B (high $1.19B, low $1.13B), average EBITDA is $371.88M (high $382.78M, low $364.6M), average net income is $224.59M (high $234.78M, low $219.16M), average SG&A $251.22M (high $258.58M, low $246.3M), and average EPS is $0.786 (high $0.822, low $0.767). SHC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.21B (high $1.25B, low $1.19B), average EBITDA is $391.89M (high $403.84M, low $384.61M), average net income is $247.83M (high $257.65M, low $241.84M), average SG&A $264.73M (high $272.81M, low $259.81M), and average EPS is $0.868 (high $0.902, low $0.847).

Did the SHC's actual financial results beat the analysts' financial forecasts?

Based on Sotera Health's last annual report (Dec 2023), the company's revenue was $1.05B, beating the average analysts forecast of $1.05B by 0.25%. Apple's EBITDA was $276.69M, missing the average prediction of $338.02M by -18.14%. The company's net income was $51.38M, missing the average estimation of $221.21M by -76.77%. Apple's SG&A was $236.67M, beating the average forecast of $228.34M by 3.65%. Lastly, the company's EPS was $0.18, missing the average prediction of $0.775 by -76.76%. In terms of the last quarterly report (Dec 2023), Sotera Health's revenue was $310.24M, beating the average analysts' forecast of $302.17M by 2.67%. The company's EBITDA was $104.02M, beating the average prediction of $97.59M by 6.60%. Sotera Health's net income was $38.68M, missing the average estimation of $73.6M by -47.45%. The company's SG&A was $60.36M, missing the average forecast of $65.92M by -8.44%. Lastly, the company's EPS was $0.14, missing the average prediction of $0.258 by -45.68%